Welcome to our dedicated page for Braxia Scientifi news (Ticker: BRAXF), a resource for investors and traders seeking the latest updates and insights on Braxia Scientifi stock.
Braxia Scientific Corp. (OTC Pink: BRAXF) has issued a series of detailed news releases that trace its evolution from a medical research and telemedicine company operating multidisciplinary mental health clinics to a corporation in the process of winding down. Earlier disclosures describe Braxia Scientific as focusing on clinics that provide ketamine treatments, and at times psilocybin treatments, for persons with depression and related disorders, combined with research into novel drugs and delivery methods.
News coverage for Braxia Scientific includes financial results, corporate updates, and strategic reviews. The company has reported on treatment volumes and revenue trends at its clinics, efforts to reduce expenses and improve efficiencies, and a formal process to explore strategic alternatives such as potential sales, mergers, asset sales, or other significant transactions. These releases provide context on how the company’s mental health clinic operations and research activities have been managed over time.
More recent news has focused on regulatory and corporate restructuring events. Braxia Scientific announced an application for a management cease trade order, the subsequent issuance of a failure-to-file cease trade order by the Ontario Securities Commission, and the suspension of trading of its shares on the Canadian Securities Exchange. Additional releases detail the approval and completion of a transaction involving the sale of all or substantially all of the company’s assets, including the assets of its wholly owned clinic operator subsidiary.
Following the asset sale, Braxia Scientific disclosed that it has minimal cash assets, a significant working capital deficiency, and plans to wind down operations with no intention to pursue further business. Investors and observers can use the news flow associated with BRAXF to understand the company’s historical clinic and research activities, its financial and regulatory challenges, and the steps leading to its current wind-down status. This page aggregates those announcements so readers can follow the sequence of events affecting Braxia Scientific over time.
Braxia Scientific Corp. (CSE: BRAX, OTC: SHRMF, FWB: 496) announced a symbol change on the OTC Market from 'SHRMF' to 'BRAXF' effective May 21, 2021. The company focuses on developing ketamine treatments for depression and related disorders, emphasizing its commitment to setting standards in mental health care. Braxia operates multidisciplinary clinics in cities like Mississauga, Toronto, Ottawa, and Montreal, aiming to lead in ketamine and psychedelic treatment research.